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Initially implicated in the pathogenesis of CFTR and HIV-1 transcription, nuclear factor TDP-43 was subsequently found to be
involved in the origin and development of several neurodegenerative diseases. In 2006, in fact, it was reported for the ﬁrst time
the cytoplasmic accumulation of TDP-43 in ubiquitin-positive inclusions of ALS and FTLD patients, suggesting the presence of
a shared underlying mechanism for these diseases. Today, diﬀerent animal models of TDP-43 proteinopathies are available in
rodents, nematodes, ﬁshes, and ﬂies. Although these models recapitulate several of the pathological features found in patients,
the mechanisms underpinning the progressive neuronal loss observed in TDP-43 proteinopathies remain to be characterized.
Compared to other models, Drosophila are appealing because they combine the presence of a sophisticated brain with the
possibility to investigate quickly and massively phenotypic genetic modiﬁers as well as possible therapeutic strategies. At present,
the development of TDP-43-related Drosophila models has further strengthened the hypothesis that both TDP-43 “loss-of-
function” and “gain-of-function” mechanisms can contribute to disease. The aim of this paper is to describe and compare the
results obtained in a series of transgenic and knockout ﬂies, along with the information they have generated, towards a better
understanding of the mechanisms underlying TDP-43 proteinopathies.
1.Introduction
Nowadays, Drosophila is one of the most widely used
model organism for studying complex genetic and biological
problems. Drosophila was introduced as an experimental
model in the early twentieth century. Although there are
several diﬀerent Drosophila species which diﬀer in habitat,
morphology, and genetic background, D. melanogaster is the
species with the highest degree of homology with humans.
Over the years, many mutants of Drosophila melanogaster
have been isolated and many transgenic strains have been
created as model systems for the study of human disease
[1], leading to the observation that more than 70% of
human loci correlated with pathological conditions have
orthologsinDrosophilamelanogaster [2].Comparedtoother
animal models used to study the mechanisms underlying
many disease onset/progression, Drosophila present several
advantages: the life span is short (from 40 to 120 days) [3];
the genome is compact, with only 4 pairs of homologous
chromosomes and roughly 13600 genes [4]. The importance
of Drosophila melanogaster is further supported by the fact
that it represents an animal model where the eﬃcacy of
putative therapeutic agents can be quickly screened and
tested [1, 5]. Altogether, therefore, these characteristics make
Drosophila an ideal model for gaining insights into the
mechanisms by which genes cause disease in humans.
In particular, in the last ten years increasing attention
has turned towards this animal in order to obtain a better
understanding of neurodegenerative disorders [1, 5]. For
this purpose, the most appealing feature of this organism
consists in its high neuronal complexity, derived from an
advanced brain capable of learning and memory, as well as
from the presence of a nervous system made up of several
specialized cytotypes belonging to ion channels, receptors,
and neurotransmitters that are present also in humans. In
conclusion, the degree of conservation between humans
and ﬂies has allowed to model consistently several human
neurodegenerative disorders in the Drosophila brain [20].
Among genes implicated in human disease, TDP-43 is
a nuclear factor recently identiﬁed as a protein capable of2 Journal of Amino Acids
playing a crucial role in the pathogenesis of FTLD, ALS, and
other neurodegenerative diseases [21–24]. In ALS and FTLD
patients, in fact, this protein (and its C-terminal fragments)
has been found as the major components of preferentially
cytoplasmicphosphorylatedinclusionspositiveforubiquitin
and tau/α-synuclein negative [25, 26]. The mechanisms
through which these inclusions may be connected with
disease are still the subjects of debate [27].
However,thefactthattheymaybeactingasacytoplasmic
protein“sink”totrapthepredominantlynuclearTDP-43has
suggested that the onset of neurodegenerative diseases might
betheconsequenceoftheprogressivenuclearlossoffunction
of TDP-43 trapped within the cytoplasmic inclusions (this
does not rule out, of course, that various “gain-of-function”
mechanisms may be playing a role in parallel) [22].
In order to clarify these issues it is therefore important
to ﬁnd a suitable animal model that expresses a functional
homologue of human TDP-43. In this respect, it is already
known that the TDP-43 ortholog of Drosophila melanogaster
(namely, TBPH) has the structure and in vitro functions
similar to the human protein, at least for the repression of
splicingofspeciﬁcexons[36,37].Therefore,inconsideration
of this considerable homology between human and fruit ﬂy
TDP-43 orthologs there is a growing interest in utilizing
Drosophilas as a model to characterize the functions of
this protein. Here, we will review the various ﬂies models
that have been developed up to now to investigate the
pathological hallmarks of the neurodegenerative diseases
related to alterations of expression of wild-type or mutant
TDP-43/TBPH.
2. StructuralDivergences andFunctional
Conservation between TDP-43 and TBPH
The TARDBP gene is a highly conserved gene throughout
evolution and orthologs of human TDP-43 have been
found in all higher eukaryotic species, including Drosophila
melanogaster. In ﬂies, the main homologue of human TDP-
43 is a protein called TBPH (UniProt, O97468 DROME).
The comparison of the longest protein isoforms shows that
the region that includes two RNA recognition motifs (RRM1
and RRM2, Figure 1(a)) is more conserved than the C-
terminal region (Figure 1(b)). In fact, pairwise amino acid
alignment highlights the presence of 59% identity and 77%
similarity between human and fruit ﬂy N-terminals/RRMs,
whereas the degree of identity and similarity of the C-
terminus regions is only 18% and 22%, respectively.
Notwithstanding these diﬀerences, many experiments
have highlighted an extremely high degree of functional
similarity and interchangeability between the human and
ﬂy proteins (see also below). First of all, both proteins
share the same preference with regards to RNA binding
speciﬁcities as recent studies have shown that TBPH is
able to preferentially bind the same consensus (UG)n rich
sequences tagged by the human ortholog [36]. Importantly,
it has also been shown that TBPH has splicing inhibitory
eﬀects overlapping those of human TDP-43 both in vitro
and in vivo.F o re x a m p l e ,in vitro assays have demonstrated
that the Drosophila TDP-43 ortholog was able to interfere
with CFTR exon splicing minigenes similarly to TDP-43
[36]. Even more strikingly, and similarly to what has been
observed for the human protein [37, 38], the TBPH mutant
without the C-terminal region lost this inhibitory activity.
This observation has provided the ﬁrst evidence that many, if
notall,characterizedfunctionsofTDP-43,arecommonboth
for the human and ﬂy protein and even extend to the same
protein regions. In keeping with this view, subsequent in
vivostudies have conﬁrmedthat C-terminal region of TBPH,
despite its structural and sequence divergence from TDP-43,
can also interact with the same nuclear partners of TDP-43
(i.e., hnRNPA2, hnRNPA1, hnRNPC, and hnRNPB1) [37].
Altogether, therefore, these observations indicate that
there is an extremely high degree of functional conservation
through evolution from ﬂies to human and this observation
has represented the starting point for using Drosophila
models to address the issue of TDP-43-dependant neurode-
generation.
3.TBPH NullAllele Drosophilas
Two complimentary approaches have been utilized for the
genetic characterization of ALS-related pathways: loss and
gain of function of the Drosophila TDP-43 ortholog and
overexpression of TDP-43 variants presenting mutations
found in ALS patients. Tables 1 and 2 summarize the TDP-
43 knocked out and transgenic ﬂies so far generated and the
most relevant phenotypic features observed in these models.
4. Loss-of-Function Models
Withregardstolossoffunction,thegeneralstrategyhasbeen
to target disruption of the TBPH gene in Drosophila in order
to analyze whether ALS-like phenotypes could be generated.
The ﬁrst TBPH-ko model used chromosomal deletions
that removed the initial part of the gene regulatory region
and the ORF [6]. Homozygous TBPH-ko ﬂies were viable
after embryogenesis and most of them were able to reach
the pupal stage and undergo metamorphosis [6]. It was
hypothesized that the progression through the ﬁrst stages
of developments is probably due to the permanence of
residual gametic TBPH. However, a high percentage of
TBPH-/-ﬂieswereunabletocompleteeclosionandremained
trapped inside the pupal cages. Furthermore, TBPH-ko ﬂies
presented a dramatic decrease in ﬂight and walking perfor-
mances with spastic and uncoordinated movements [6]. As a
result, the life span of these ﬂies was signiﬁcantly reduced.
The analysis of presynaptic terminals at neuromuscular
junctions (NMJs) highlighted that the TBPH-/-larvae show
a reduction of axonal branches and synaptic boutons present
inside the muscles [6].
The second loss-of-function model was generated with
a point mutation (G>A) that introduced a stop codon at
residue 367 (Q367X) [7]. The semilethality of the homozy-
gosityforTBPHdeletionwasconﬁrmedbyﬂieshomozygous
for the Q367X allele or ﬂies treated with tubulin-Gal4-TBPH
RNAi knockdown [7]. This study showed that TBPH canJournal of Amino Acids 3
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Figure 1: Comparison between human and ﬂy TDP43. (a) Schematic representation of each domain (and amino acid position) in the two
orthologs. (b) Alignment of the human (TDP-43) and ﬂy (TBPH) proteins. The longest isoforms of human and ﬂy proteins were used
for this analysis (Uniprot accession no. Q13148 and O97468, resp.). Amino acids identical (|) or similar (:) between the two proteins are
indicated. Bold residues indicate the RNA recognition domains, RRM1 and RRM2. The RNP consensus sequences present in each RRM
are highlighted (bold and underlined). All potential phosphorylation sites within human TDP-43 are indicated by asterisks. Importantly
diﬀerent studies have found a strong link between hyperphosphorylation at Serine379, Serine403, Serine404, Serine409, Serine410, and the
inclusions of TDP-43 in FTLD-U/ALS [28–34].
regulate dendritic branching in ddaE and ddaF neurons.
In fact, whereas TBPH silencing (both by homozygosity
for Q367X mutation or by whole-body RNAi) decreased
dendritic branching, TBPH overexpression had the opposite
results [7].
Most importantly, both studies demonstrated that the
functions of the human TDP-43 overlapped those of TBPH
alsoinvivo.Infact,itwasshownthatoverexpressionofTDP-
43 could eﬃciently rescue the phenotype caused by TBPH
deﬁciency.4 Journal of Amino Acids
Table 1: Flies models of TDP-43 proteinopathies. Elav-GAL4 and 1407-GAL4 are pan-neuronal drivers; GMR-Gal4 driver is eye speciﬁc.
D42-Gal4 driver is speciﬁc for motor neurons; OK107-GAL4 driver is speciﬁc for mushroom body. MHC-GAL4 and 24B-GAL4 drivers are
muscle speciﬁc; Repo-GAL4 driver is glia speciﬁc.
Loss of function (null allele) Gain of function/RNAi transgenes Phenotypes
Feiguin
et al. [6]
Generation of mutants carrying
chromosomal deletions. Two
excised lines (TBPH D23 and
TBPH D142) show small 1.6 and
0.8 kb deletions, respectively
(that partially removed part of
TBPH regulatory and coding
regions)
Generation of transgenic ﬂies with TBPH
and hTDP-43 add back in TBPH
knockout backgrounds using the
D42-GAL4 or elav-GAL4 drivers.
Homozygous TBPH-KO ﬂies were viable after
embryogenesis. Homozygous ﬂies that got rid
of the external cuticle presented dramatic
locomotive defects with spastic,
uncoordinated, movements, incapacity to ﬂy
or walk normally and reduced life span. In
TBPH-KO larvae, the number of axonal
branches and synaptic boutons inside the
muscles were reduced in the presynaptic
terminals. Loss of TDP-43 function alters the
morphological organization of the NMJ.
TBPH RNAi lines were obtained. RNAi caused similar locomotive defects
Lu et al.
[7]
Generation of null allele carrying
nonsense mutation with a single
nucleotide change (G>A
introduced a stop codon at
codon 367 in TBPH-43 Q367X)
Generation of hTDP-43WT and hTDP-43
Q331K or hTDP- 43 M337V
UAS-hTDP-43 transgenic ﬂies.
Homozygosity for TBPH-43Q367X was
semi-lethal, with some mutant adult ﬂies
surviving to adulthood. The number of small
terminal dendritic branches was increased by
overexpression of TBPH-43. Their localization
was concentrated near the cell body of ddaE
neurons. Ectopic expression of Q331K and
M337V mutant proteins promoted dendritic
branching to a much lesser extent than
wild-type hTDP-43.
Expression of UAS-TBPH-43 RNAi
(38377 or 38379, VDRC) driven by
tubulin-Gal4
RNAi resulted in a similar lethal phenotype.
Voigt et al.
[8]
Generation of synthetic mutants
(TDP-43SM) and ALS/FTLD-linked
TDP-43MS TBPH-43 transgenic
UAS/Gal4 ﬂy lines: TDP-43SM variants
(WT; ΔNLS; F147L/F149L; CTF, lacking
the N-terminal portion including
RRM1). ALS/FTLD-linked TDP-43MS
variants (A315T;G287S;A382T;N390D).
All TDP-43 variants but TDP-43CTF and
TDP-43FFLL caused premature lethality. All
TDP-43 variants caused reduction in life span.
Dose dependency of TDP-43-mediated
neurotoxicity (TDP-43WT and TDP-43NLS).
Although still alive, 20d-old TDP-43 WT
expressing ﬂies appeared paralytic, hardly
showed coordinated movement, and failed to
climb. Loss of motor neurons caused by
TDP-43WT > TDP-43A315T and
TDP-43DNLS.
Fiesel et al.
[9]
Generation of null allele where
the entire CDS of the TBPH gene
was deleted
TBPH -/- animals die as second-instar larvae.
The ability of hTDP-43 to bind and regulate
expression of the HDAC6 mRNA is conserved
also by TBPH and dhdac6 in Drosophila.
Hanson
et al. [10]
To test the consequences of the
TDP-43/UBQLN interaction in vivo,
transgenic Drosophila lines were created
with cDNAs encoding either wild-type
human TDP-43 or human UBQLN under
UAS/GAL4 control. GMR-Gal4 driver
was used to express human TDP-43 in
the ﬂy eye. D42-Gal4 driver was used to
express TDP-43 exclusively in motor
neurons.
Overexpression of TDP-43 is toxic in the ﬂy
eyes. TDP-43 toxicity is both dose dependent
and age dependent. TDP-43 expression in
motor neurons reduces life span. UBQLN
increases TDP-43 toxicity in both Drosophila
and mammalian systems.
Li et al.
[11]
Expression of hTDP-43 in Drosophila
eyes with GMR-Gal4 driver beginning at
the third instar larva. Overexpressed
hTDP-43: WT or mutant T202
(containing the carboxyl-terminal
glycine-rich domain but lacking the
amino-terminal RNA recognition motif).
Overexpression of TDP-43 is toxic in the ﬂy
eyes. Both overexpression and silencing of
hTDP-43 in mushroom bodies causes axonal
and neuronal loss. Expression of hTDP-43 in
motor neurons causes formation of aggregates
in cell bodies and axons, as well as axon
swelling. hTDP-43-expression causes
age-dependent reduction in ﬂies motility.Journal of Amino Acids 5
Table 1: Continued.
Loss of function (null allele) Gain of function/RNAi transgenes Phenotypes
Expression of hTDP-43 in Mushroom
Bodies with OK107-Gal4 driver
Expression of hTDP-43 in a small subset
of MNs at the adult stage with RN2-Gal4
driver.
TBPH RNAi lines were obtained.
Ritson
et al. [12]
Generation of transgenic ﬂies expressing
human WT or mutant TDP-43 using the
UAS/GAL4 system. Used NES-mutant
TDP-43 (nuclear) and NLS-mutant
TDP-43 (cytoplasmic). TDP-43 (WT or
mutant) under control of the driver
fkh-GAL4.
In the eye, expression of dVCP-wt caused a
modest phenotypic change, whereas matched
expression of the R152H and A229E mutants
caused severe external rough eye phenotypes
with necrotic patches and vacuolar
degeneration. Generation of transgenic lines
overexpressing TBPH resulted in a degenerative
phenotype when targeted to the eye.
Expression of the ALS-causing mutation
M337V (leads to toxicity associated with
cytoplasmic redistribution of TDP-43).
The ALS-causing mutation M337V expressed
in vivo leads to toxicity associated with
cytoplasmic redistribution of TDP-43.
Flies transgenic for UAS-dVCP (WT or
mutant), UAS- TBPH, and UAS-TDP-43
(WT or mutant) were generated
Coexpression of exogenous TBPH with dVCP
R152H enhanced degeneration associated with
mutant VCP and conﬁrming the genetic
interaction.
TBPH RNAi lines were obtained.
Estes et al.
[13]
Transgenic lines were generated to
express TBPH and hTDP-43 wild-types
and A315T mutants. Gal4 drivers used
included the GMR-Gal4 and the
D42-Gal4.
Overexpression of WT- and A315T-TDP-43 is
toxic for the retina of ﬂy eyes. TBPH-wt is
100% lethal when overexpressed at higher
levels (by raising the temperature at 29◦C).
Wild-type and mutant TDP-43 create axonal
aggregates in the developing eyes.
Motor neurons expressing TDP-43 variants
exhibit morphological defects at the NMJ
synapse. Locomotor activity, viability, and
survival are impaired regardless of the presence
of detectable TDP-43 cytoplasmic aggregates.
TBPH RNAi lines were obtained.
TBPH-RNAi enhances the toxic eﬀect of both
wild-type and A315T hTDP-43 expression in
motor neurons.
Guo W.
et al. [14]
Expression of hTDP-43 (WT or A315T)
with OK371-Gal4 driver in subsets of
motor neurons.
Flies often failed to eclose and surviving ﬂies
were smaller than control ﬂies. Neurotoxicity
and motor neuron deﬁcits with mutant
TDP-43. Expression of either wild-type or
A315T mutant TDP-43 caused axonal
abnormalities. Motor neurons expressing
wild-type or mutant TDP-43 showed axonal
swelling. Expression of A315T caused frequent
ﬂy death before the 3rd-instar stage. Surviving
ﬂies showed a marked axonal loss. In the
remaining axons we detected severe damage,
including axon swelling, axon thinning, and
defects in axonal integrity. Expression of
A315T (compared to wild-type) TDP-43
caused higher neuronal loss.
Lanson
et al. [15]
The genetic interaction between human
FUS/TLS and TDP-43 was tested by using
transgenic TDP-43 ﬂies described by
Ritson et al.
Ectopic expression of mutant FUS/TLS leads to
neurodegeneration in Drosophila. Genetic
interaction between human FUS/TLS and
TDP-43 tested by using transgenic TDP-43 ﬂies
described by Ritson et al. Eye expression of
FUS WT or TDP-43 WT alone did not cause
signiﬁcant degeneration.6 Journal of Amino Acids
Table 1: Continued.
Loss of function (null allele) Gain of function/RNAi transgenes Phenotypes
Coexpression of both proteins caused
moderate eye degeneration. Co-expression of
FUS WT with M337V-TDP-43 led to severe eye
degeneration. Co-expression of R521H FUS
with TDP-43 WT synergistically enhanced the
degeneration.
Li et al.
[16]
GMR-Gal4 and elav-Gal4 were used to
drive expression of wt (fTDP) and three
truncated forms of TDP with N-terminal
104 (ND104), 207 (ND207), and 251
(ND251) amino acids deleted.
ND104, ND207, and ND251 were concentrated
and formed aggregates in cytoplasm because of
the lack of nuclear localization signal (NLS).
The pattern of insoluble ND251 highlighted a
shorter fragment and high molecular weight,
similar to what is observed in
TDP-ALS/FTLD-U inclusions.
Diﬀerent GAL4 drivers were used to
induce tissue-speciﬁc TBPH knockdown
(Elav4;OK107; D42; MHC).
Pan-neuronal TBPH knockdown caused
reduction in the moving abilities of larvae.
Lin et al.
[17]
Motor neurons TBPH overexpression reduced
ﬂy locomotor activities, along with a decrease
of the number of boutons and axon branches
at NMJ. TBPH overexpression in the
mushroom bodies caused smaller axonal lobes
and learning deﬁciency. Mushroom
body-speciﬁc TBPH-knockdown did not aﬀect
the structure of the mushroom bodies, but
caused modest reduction in the learning
ability. TBPH-overexpression caused the
formation of cytosolic TBPH aggregates.
Diﬀerent GAL4 drivers were used to
induce tissue-speciﬁc TBPH-knockdown
(Elav4; Repo; 24B; GMR).
Expression of TDP-43 wild-type is toxic for
Drosophila eyes, muscles, and glia.
Miguel
et al. [18]
Both nuclear and cytoplasmic TDP-43
accumulations are toxic for neurons (regardless
of the formation of inclusions). Expression of
human TDP-43 in adult ﬂies neurons results in
abnormally phosphorylation of the
disease-speciﬁc Ser409/Ser410 residues and
presence of high molecular weight forms in
ﬂies.
Godena
et al. [19]
The previously generated TBPH-ko ﬂy
lines (Feiguin, 2009) were used to
characterize the pathological
consequences of TBPH-43 altered
function in the Drosophila
neuromuscular junctions during larval
development.
TDP-43 is necessary for presynaptic
microtubule organization: TBPH was found to
modulate the expression of futsch, a
neuron-speciﬁc microtubule binding protein
ortholog of the human MAP1B important for
maintaining the microtubule integrity during
neuromuscular junctions expansion.
A third null allele model of TBPH was generated by
deleting the whole coding sequence of the TBPH gene
[9]. Contrary to what was observed in previous reports,
homozygous TBPH -/- ﬂies died at the second instar larval
stage. It should be noted, however, that this null allele
model was used only to conﬁrm in vivo the data obtained
in vitro with human cell lines and no further molecular
characterization was carried out. In particular, this model
was used to conﬁrm that the ability of TDP-43 to bind and
regulate expression of the HDAC6 mRNA was conserved
also by TBPH in Drosophila [9]. In conclusion, a proper
comparison with the two previous models will have to await
for a more extensive characterization of this model.
Finally, a fourth null allele model of TBPH was created
by deletion of 932bp within the 5  end of TBPH [17].
Similarly to the other models [6, 7], early lethal phenotype
with alteration of locomotion was observed both in larvae
and in the adult ﬂies. On the other hand, the number of
the synaptic boutons in the NMJ of these ﬂies was increased
(while it was decreased in the other models). The reasons for
this discrepancy remain still unknown.
Taken together, these studies suggest that the genetic
background can signiﬁcantly modulate or modify the eﬀects
of the genomic mutations. However, all these initial reports
are strongly in agreement that depletion of TDP-43/TBPH
can trigger neurodegeneration.Journal of Amino Acids 7
Table 2: Ectopic expression of TDP-43 mutants.
Human TDP-43
mutations
Q331K Eye [7]
M337V Eye [7]
M337V Eye [12]
M337V Eye [15]
A315T Eye [13]
G287S Pan-neural,
ubiquitary [8]
A315T Pan-neural,
ubiquitary, eye [8]
G348C Pan-neural,
ubiquitary [8]
A382T Pan-neural,
ubiquitary [8]
N390D Pan-neural,
ubiquitary [8]
Other mutants
TDP-43 T202 Eye [11]
TDP-43 NES-mut Eye [12]
TDP-43 NLS-mut Eye [12]
TDP-43 ΔNLS Eye, pan-neural,
ubiquitary [8]
TDP-43 FFLL Eye, pan-neural,
ubiquitary [8]
TDP-43 CTF Pan-neural,
ubiquitary [8]
TBPH F/L 150–152 Pan-neural [19]
hTDP-43mutNES Eye, muscle,
glia, pan-neural [18]
hTDP-43mutNLS Eye, muscle,
glia, pan-neural [18]
TDP-43 T202 contained only the C-terminal domain (the N-terminal RRM motifs are lacking). TDP-43 ΔNLS lacked a functional nuclear localization signal.
TDP-43 FFLL contained two missense mutations (F147L/F149L) into the ﬁrst RNA recognition motif (RRM1) that abolished TDP-43 RNA-binding function
[35]. TBPH F/L 150-152 contained point mutations of the two Phe > Leu in RNP-2 of RRM1 corresponding to human (F147L and F149L). TDP-43 CTF
consisted in the C-terminalfragment (206–414) similar to those found in cytosolicaggregatesof ALS/FTLD patients.TDP-43 NLS-mut and hTDP-43mutNLS
were mutants in the nuclear localization sequence (NLS). TDP-43 NES-mut and hTDP-43mutNES were mutants in the nuclear export sequence (NES).
5. TDP-43 Transgenic Flies
As intuitively obvious, a complimentary approach to the
creation of TBPH-ko ﬂies consists in the ubiquitous or
tissue-speciﬁc overexpression and/or silencing of this factor
byusingtheGal4-UASsystem.Consistently,diﬀerentreports
found that the expression of the wild-type form of TDP-43
(both TBPH and TDP-43) in the Drosophila eye causes a
severe retinal degeneration with loss of cells [10–13, 18].
In a likewise manner, expression of TDP-43 in mush-
room bodies caused neuronal death and axonal loss [11]
and overexpression of TDP-43 in motor neurons caused
morphological and functional defects associated with cyto-
plasmic and axonal aggregation as well as axonal swelling
[11]. Diﬀerent TDP-43 toxicity has been also associated with
its subcellular accumulation. For example, it was shown
that cytoplasmic accumulation of TDP-43 is suﬃcient to
induce degeneration in neuronal and nonneuronal tissues
[12, 18]. Cytoplasmic inclusions of TDP-43 were toxic in
eyes, muscles, and glia, whereas both cytoplasmic or nuclear
TDP-43 accumulation were toxic in neurons of adult ﬂies
[18]. Finally, in some cases the ectopic expression of TDP-
43 in eyes led to the detection of nuclear detergent-insoluble
high-molecular-weightTDP-43aggregates[11,12].Similarly
to what is observed in mammalian systems [39, 40], TDP-
43 toxicity was associated with increased levels of both
nuclear and cytoplasmic TDP-43, independently from the
presence of inclusions [18]. Indeed, a consistent observation
in diﬀerent reports was that the ectopic TDP-43 expression
led to a dose- and age-dependent toxicity. In fact, the onset
time and the severity of locomotion defects and neuronal
loss were proportional to the levels of TDP-43 expression
[8, 10, 11, 13, 18].
Another distinguishing feature of TDP-43 proteinopa-
thies is the presence of mutations occurring mainly within
the C-terminal region of the TDP-43 protein (that have been8 Journal of Amino Acids
identiﬁed mostly in both sporadic ALS and FALS patients
[41]). Overexpression of artiﬁcial or disease-related TDP-
43 mutants displayed variable levels of toxicity (see Table 1)
probably depending on the exact level of overexpression with
respect to wild-type protein. In fact, it is quite challenging
to separate the eventual toxic eﬀects of the mutation with
respect to the general toxicity induced by TDP-43 overex-
pression. The expression of the ALS/FTLD-linked TDP-43
mutationsA315TandM337Vinﬂiesresultedinanincreased
neurodegeneration (Table 2)[ 7, 8, 12, 13, 15], consistently
with the phenotypes exhibited by the transgenic rodent
models for the same mutations [39, 42, 43]. On the other
hand, other disease-causing mutations expression in ﬂies
causedavariableincrementoftoxicity(Table 2)[7,8,13,15].
Other types of more artiﬁcial mutations, however, were
found to be more consistent with regards to their eﬀects.
For example, this was the case for the impact of mutations
withinthenuclearlocalizationandnuclearexportsequences.
In general, while the expression of the TDP-43 NLS-mutant
in the ﬂy eyes resulted in a stronger [12, 18]o rc o m p a r a b l e
[8] degenerative phenotype compared to the eﬀects of the
TDP-43 wild-type expression, the TDP-43 NES-mutant was
associated with a normal phenotype [12, 18].
Finally, and most importantly, it is clear that the RNA-
binding activity of TDP-43 is crucial for TDP-43 toxicity [8,
11, 19], whereas the C-terminal end seems to have milder
impact on longevity, neuronal loss, and locomotion [8].
6. GeneticInteractionswith TDP-43
in Drosophila
A growing body of evidence indicates that TDP-43 abnor-
malities are not limited to ALS and FTLD but are present in
many neurodegenerative and myodegenerative diseases [44–
46]. Of course, several other genes have also been implicated
in the pathogenesis of these diseases. Diﬀerent studies have
therefore addressed the problem of possible interactions
between TDP-43 and some of these genes, in order to
highlight the presence of common pathologic pathways or
the existence of genetic modiﬁers of disease severity [41, 47–
52].
The Valosin-Containing Protein (VCP) is a molecular
chaperoneVCPthatsegregatesubiquitinatedsubstratesfrom
multimeric protein complexes. Autosomal dominant muta-
tions in the VCP gene have been identiﬁed in the Inclusion
Body Myopathy associated with Paget’s disease of bone
and frontotemporal dementia (IBMPFD; MIM167320).
Mutations in this gene exhibit variable penetrance and
cause progressive muscular bony and neuronal degeneration
with lethal exitus [53]. Most importantly, TDP-43 has
been found within ubiquitinated cytoplasmic inclusions
in the muscles of IBMPFD patients [44, 47]. In order
to identify genes able to suppress neurodegeneration, a
genetic screening was undertaken in a Drosophila model
of IBMPFD created with disease-causing VCP mutations
[12]. In this way, a genetic interaction between VCP and
TDP-43 was highlighted (Figure 2(a)). In this model, it
was observed that (1) the expression of pathogenic VCP
mutants caused cytoplasmic TDP-43 accumulation in vivo;
(2) the intracellular redistribution of TDP-43 was suﬃcient
to induce degeneration; (3) enhancement of toxicity was
obtained following coexpression of the TDP-M337V mutant
with mutant dVCP [12]. These ﬁndings are consistent with
a knockin IBMPFD mouse model that exhibited progressive
cytoplasmic accumulation of TDP-43 and ubiquitin-positive
inclusion bodies in quadriceps myoﬁbrils and brain [48].
Thus, both animals apparently represent useful models for
preclinical studies regarding this pathology.
Another gene found mutated in familial and sporadic
ALS is the one coding for fused in sarcoma/translocated-in-
liposarcoma (FUS/TLS) protein [54, 55]. Similarly to TDP-
43, FUS/TLS is a nuclear RNA-binding protein ubiquitously
expressed [41]. Several ALS-causing mutations in this pro-
tein cause the redistribution of the protein to the cytoplasm
and this accumulation leads to the formation of cytoplasmic
inclusions in neurons and glial cells [54–56]. The coexistence
of FUS- and TDP43-immunoreactive inclusions in an ALS
patient carrying the TDP-43 G298S mutation suggested the
FUS/TLS and TDP-43 might share some pathologic mecha-
nisms leading to ALS [57]. Subsequent studies demonstrated
that FUS/TLS and TDP-43 interact physically and function-
ally [41, 58, 59]. To better investigate this interaction, two
DrosophilamodelsofFUS/TLS-mediatedALSwereobtained
by generating a null allele of the ﬂy FUS/TLS ortholog [60]
and by expressing mutant human FUS/TLS in eyes and
motor neurons [15]. In these models, the genetic interaction
between FUS/TLS and TDP-43 was demonstrated through
the worsening of neurodegenerative phenotypes following
coexpression of wild-type or mutant FUS/TLS and wild-type
or mutant TDP-43 [15, 60]( Figure 2(b)). Furthermore, it
was conﬁrmed that also the FUS and TDP-43 ﬂy orthologs
associatewitheachotherinanRNA-dependentcomplex[60]
as reported for the human proteins [50, 58, 61].
Finally, recent studies have found that ubiquilin 1
(UBQLN) is another potential TDP-43 interactor [62].
UBQLN is a cytosolic protein involved in targeting mis-
folded proteins to the proteasome for degradation [63]a n d
implicated in the pathogenesis of some neurodegenerative
diseases [64, 65]. Experiments in mammalian cells showed
that TDP-43 and UBQLN colocalize in cytosolic aggre-
gates [62] and suggested that UBQLN might be involved
in pathway controlling TDP-43 degradation. In order to
investigate its genetic interaction with UBQLN, a Drosophila
modelofTDP-43proteinopathywasgenerated(Figure 2(c)).
Contrarilytoexpectations,however,coexpressionofUBQLN
increased the toxicity of TDP-43 without aggregation
although the levels of TDP-43 were decreased and these
results were further conﬁrmed also in a mammalian cell line
[10].
Taken together, these observations provide evidence that
many aspects of neurodegeneration are conserved from
Drosophila to vertebrates and strengthen the utilization of
the Drosophila models to study systematically modulators of
TDP-43-induced neurodegeneration.Journal of Amino Acids 9
Mutant
VCP
(R155H; A232E)
TDP-43
VCP-TDP-43 
(1) Cytoplasmic TDP-43 accumulation caused by the expression
of pathogenic VCP mutants
(2) Intracellular redistribution of TDP-43-induced degeneration
(3) Enhancement of toxicity caused by coexpression of the
TDP-M337V mutant and mutant dVCP
Genetic interaction
↑
(a)
TDP-43 FUS/TLS
(wt; R521H; R518K) (wt; M337V)
FUS/TLS-TDP-43
Genetic interaction
(1) Mild enhancement of toxicity in D.m. eyes caused by coexpression
of the TDP-wt and FUS/TLS wt. Synergistic enhancement of toxicity
in eyes caused by coexpression of TDP-wt and FUS/TLS mutants or
of TDP-43 M337V mutant and FUS/TLS wt
(2) FUS/TLS and TDP-43 Drosophila orthologs associated with each
other in an RNA-dependent complex
(3) FUS/TLS Drosophila ortholog works together with and downstream
of TDP-43 in a common genetic neuronal pathway
↑↑
(b)
UBQLN
UBQLN-TDP-43 
(1) UBQLN enhanced TDP-43 motor neuron toxicity
(2) Coexpression of UBQLN increased the toxicity of
TDP-43 without aggregation
Genetic interaction
UBQLN promotes the 
clearance of cytosolic TDP-43
↑
(c)
Figure 2: Genetic interactions of TDP-43/TBPH. (a) Schematic representation describing the eﬀects of valosin-containing protein (VCP7)
gene overexpression on TDP-43-toxicity in Drosophila melanogaster. (b) Schematic representation describing the eﬀects of FUS/TLS
gene overexpression on TDP-43-toxicity in Drosophila melanogaster. (c) Schematic representation describing the eﬀects of UBQLN gene
overexpression on TDP-43-toxicity in Drosophila melanogaster. The lines of evidence supporting the genetic interaction between the TDP-
43 and these other genes are schematically summarized.
7. GenesandProteinsRegulated byTBPH
in Drosophila
At present, not many TBPH-interacting molecules have
been identiﬁed that can possess a direct link with disease.
Two exceptions are represented by the validated interac-
tion between TBPH and the HDAC6 and futsch mRNAs
(Figure 3).
The histone deacetylase 6 (HDAC6) gene has been impli-
cated in the pathogenesis of Alzheimer’s disease and Parkin-
son’s disease by linking together two protein degradation
pathways (the ubiquitin proteasome system and autophagy)
[66–69]. Recently, HDAC6 mRNA was identiﬁed as the ﬁrst
molecular target of TDP-43 conserved both in mammalian
and invertebrates [9]. The levels of HDAC6 mRNA and
protein decreased upon TDP-43 silencing and this eﬀect was10 Journal of Amino Acids
TBPH
HDAC6
Targets
Interaction Levels
mRNA Yes
Protein
Futsch
=
Interaction Levels
mRNA Yes
Protein
↑
↑
↑
Figure 3: HDAC6 and futsch levels are controlled by TBPH in
Drosophila. Two genes are currently described as direct targets
of TBPH in Drosophila melanogaster. Both HDAC6 and futsch
mRNAs are bound by TBPH. In particular, TBPH silencing
decreases HDAC6 mRNA and, as a consequence, protein levels.
On the other hand, TBPH silencing causes a drop only in futsch
protein levels but not in mRNA expression, suggesting in this
case an involvement of TDP-43 in either the mRNA transport or
translations systems.
associated with accumulation of acetyl-tubulin, the major
HDAC6 substrate [9]. It should also be noted that follow-
up studies found that TDP-43 and FUS/TLS form a complex
with HDAC6 [61]. These ﬁndings, therefore, suggested the
possibility that alterations of TDP-43 or FUS/TLS might
deregulate HDAC6 functions and this event could be crucial
for ALS pathogenesis.
In parallel, starting from the observation by diﬀerent
research groups that the loss of TBPH in Drosophila alters
the morphological organization of the NMJ [6, 13, 17], fur-
ther molecular characterization of the ﬁrst model of TBPH-
ko Drosophilas focused on possible alterations of elements
important for the cytoskeletal organization at synaptic level.
Among all the tested proteins, a consistent reduction in the
proteinlevelsof futschwasobservedintheheadsofTBPH-/-
ﬂies[19].TheFutschproteinisahomologofhumanMAP1B
necessary for proper axonal and dendritic growth [70]. In
this study, it was shown that the TBPH protein directly
interacts with futsch mRNA without aﬀecting its stability or
splicing proﬁle. However, since futsch protein levels were
decreased in TBPH -/- animals, this observation suggested
that TBPH might be somehow involved in the posttranscrip-
tional regulation of futsch expression [19]. This observation
provided additional insights into the physiological roles of
TDP-43 and into the potential mechanisms underlying ALS
andtheneurodegenerativediseasesassociatedwithalteration
of TDP-43.
8. Concluding Remarks
Altogether, the studies with Drosophila models have allowed
us to make several general observations.
(1) The data gained so far from these models signi-
ﬁcatively overlap most of the observations made in
human patients and in rodent models, so strengthen-
ing the usefulness of the fruit ﬂy in investigating the
role played by TDP-43 protein abnormalities in ALS
and other neurodegenerative diseases.
(2) Similarly to what is observed in rodent models, both
overexpression and silencing of TDP-43/TBPH in
Drosophila produce neurodegeneration. Beyond the
particular attention that must be reserved to the
expression levels of TDP-43 mutants, whose eﬀect
should be tested speciﬁcally for any model, these
observations also suggest that events able to modify
the expression of TDP-43 in humans might elicit
neuronal dysfunctions even before the appearance of
pathological TDP-43 inclusions.
While Drosophila models conﬁrm that toxicity occurs
regardless of inclusions, the relevance of the cytoplasmic
accumulation for the pathology remains an open question.
Inﬂies,expressionofmutantsaccumulatinginthecytoplasm
showed an increase in toxicity, but a NLS mutant TDP-43
expressed in C. elegans, although cytoplasmic, did not result
in alteration of locomotion and this observation led to the
suggestion that nucleus is the primary site of the TDP-43
toxicity [71].
(1) Diﬀerent Drosophila models support the hypothesis
that TDP-43 toxicity depends also on retaining
the ability to bind RNA targets [8, 11, 19]. This
observation further strengthens the hypothesis that
the “loss of function” within nuclei is crucial for
development of the disorder.
(2) The carboxy-terminal domain seems to have a
prominent role in the pathogenesis of human dis-
eases. In fact, most mutations found in patients lie
within this domain (for a recent review see [28]).
Intriguingly,althoughtheC-terminaldomainisquite
diﬀerent in human and ﬂy, the splicing regulation by
human and Drosophila TDP-43 requires its presence.
In fact, both TDP-43 and TBPH mutants devoid of
this region lack splicing-modifying capacity. There-
fore, although the structural conservation of this
region is low in human and ﬂies, some functions
potentially associated with neurodegeneration have
certainly been conserved through evolution.
(3) Several studies have addressed the pathogenic role
of hyperphosphorylation on the formation of TDP-
43 inclusions [28–34]. It should be noted that none
of the potential phosphorylated sites within the C-
terminal region is conserved in ﬂies (Figure 1(b)).
However,Drosophilaalongwithcellularmodelswere
also created to investigate this aspect by expressing
human TDP-43 carboxyl terminal fragment [16].
Contrary to the previous, this study has suggested
that phosphorylation occurs after aggregation and
that aggregation propensity of TDP-43 could be
reduced by hyperphosphorylation. The discrepancy
between these results and previous studies could
be ascribed to the diﬀerent systems used for the
characterizations.Journal of Amino Acids 11
(4) Age-dependent degeneration is an important feature
of neurodegenerative diseases. The investigations
aimed at understanding the relevance of aging in
aﬀecting TDP-43 expression in humans and its pos-
sible association with Alzheimer were not conclusive
[72]. At present, some of the Drosophila models of
TDP-43-pathologies described in this paper support
the hypothesis that aging can impact on the neu-
rodegeneration caused by this nuclear factor [11,
13, 17]. However, additional studies are required to
understand how many observation made in these
ﬂies models regarding this particular issues can be
generalized to humans.
For all these reasons, fruit ﬂies remain an appealing
system in which to continue the characterization of the
pathogenesis of TDP-43 proteinopathies through the screen-
ing of modiﬁer genes or the search for drugs useful for the
prevention and cure of neurodegenerative diseases.
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